Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press49510.17650/1726-9776-2015-11-3-96-100CLINICAL CASEКЛИНИЧЕСКИЙ СЛУЧАЙLong-term disease control in advanced renal cell cancer with brain metastases with pazopanib (case report and literature review)Длительный контроль распространенного почечно-клеточного рака с метастазами в головной мозг на фоне терапии пазопанибом (клинический случай и обзор литературы)ChernovaV. V.ЧерноваВ. В.
Russian Federation
zamvera@yandex.ruVolodinaL. N.ВолодинаЛ. Н.
Russian Federation
GrigorievA. V.ГригорьевА. В.
Russian Federation
SmirnovA. I.СмирновА. И.
Russian Federation
ShustovaE. V.ШустоваЕ. В.
Russian Federation
ZhuravlеvaO. P.ЖуравлеваО. П.
Russian Federation
BublikovaM. P.БубликоваМ. П.
Russian Federation
VizhgorodskayaV. V.ВижгородскаяВ. В.
Russian Federation
ShomovаM. V.ШомоваМ. В.
Russian Federation
MatyashM. G.МатяшМ. Г.
Russian Federation
Ryazan Regional Clinical Oncological DispensaryГБУ РО «Рязанский областной клинический онкологический диспансер»Russia, 390047, Ryazan, Sportivnaya St., 13Россия, 390047, Рязань, ул. Спортивная, 13NovartisНовартисNovartis Pharma LLC125315, Москва, Ленинградский просп. 72, корп. 33 bldg., 72 Leningradskiy prospect, Moscow, 12531530092015113961002409201524092015https://oncourology.abvpress.ru/oncur/article/view/495

We report the case of advanced clear cell renal cell carcinoma with brain, pulmonary, hepatic and bone metastases treated with pazopanib.We observed the complete response in brain metastases and stable extracranial disease after 4 years of the treatment. According to the literature review this is the first reported case of complete response to pazopanib in brain metastases in renal cell carcinoma.

Представлен клинический случай, демонстрирующий длительный контроль распространенного светлоклеточного почечно-клеточного рака с метастазами в головной мозг, легкие, печень, кости при применении пазопаниба. Показано, что эффект сохраняется в течение 4 лет; наблюдается полный ответ в отношении метастазов в головной мозг при стабилизации экстракраниального метастатического процесса. Как показывает обзор литературы, наше наблюдение является первым опубликованным описанием случая полного ответа со стороны метастазов в головной мозг при применении пазопаниба.

renalcellcarcinomaclear cellbrainmetastasesintracranial metastasesvisceral metastasesbone metastasestargetedtherapytyrosine kinase inhibitorsVEGFR inhibitorspazopaniblong term survivallong term responsecomplete responseпочечно-клеточный раксветлоклеточный ракметастазы в головной мозгвнутричерепные метастазывис- церальные метастазыметастазы в коститаргетная терапияингибиторы тирозинкиназингибиторы VEGFRпазопанибдлительная выживаемостьдлительный ответполный ответ1. Procopio G., Sabbatini R., Porta C. et al. Optimizing further treatment choices in short- and long-term responders to firstline therapy for patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther 2012;12(8): 1089–96.Procopio G., Sabbatini R., Porta C. et al. Optimizing further treatment choices in short- and long-term responders to firstline therapy for patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther 2012;12(8): 1089–96.2. Posner J.B., Chernik N.L. Intracranial metastases from systemic cancer. Adv Neurol 1978;(19):579–92.Posner J.B., Chernik N.L. Intracranial metastases from systemic cancer. Adv Neurol 1978;(19):579–92.3. Saitoh H. Distant metastasis of renal adenocarcinoma. Cancer 1981;48(6): 1487–91.Saitoh H. Distant metastasis of renal adenocarcinoma. Cancer 1981;48(6): 1487–91.4. Harada Y., Nonomura N., Kondo M. et al. Clinical study of brain metastasis of renal cell carcinoma. Eur Urol 1999;36(3):230–5.Harada Y., Nonomura N., Kondo M. et al. Clinical study of brain metastasis of renal cell carcinoma. Eur Urol 1999;36(3):230–5.5. Shuch B., La Rochelle J.C., Klatte T. et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008;113(7):1641–8.Shuch B., La Rochelle J.C., Klatte T. et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008;113(7):1641–8.6. Verma J., Jonasch E., Allen P. et al. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.Cancer 2011;117(21):4958–65.Verma J., Jonasch E., Allen P. et al. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.Cancer 2011;117(21):4958–65.7. Mori Y., Kondziolka D., Flickinger J.C. et al. Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 1998;83(2):344–53.Mori Y., Kondziolka D., Flickinger J.C. et al. Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 1998;83(2):344–53.8. Shuto T., Inomori S., Fujino H., Nagano H.J. Gamma knife surgery for metastatic brain tumors from renal cell carcinoma. Neurosurg 2006;105(4):555–60.Shuto T., Inomori S., Fujino H., Nagano H.J. Gamma knife surgery for metastatic brain tumors from renal cell carcinoma. Neurosurg 2006;105(4):555–60.9. Sheehan J.P., Sun M.H., Kondziolka D. et al. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 2003;98(2):342–9.Sheehan J.P., Sun M.H., Kondziolka D. et al. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 2003;98(2):342–9.10. Murata J.I., Sawamura Y., Terasaka S. et al. Complete response of a large brain metastasis of renal cell cancer to interferonalpha: case report. Surg Neurol 1999;51(3):289–91.Murata J.I., Sawamura Y., Terasaka S. et al. Complete response of a large brain metastasis of renal cell cancer to interferonalpha: case report. Surg Neurol 1999;51(3):289–91.11. Takita T., Tanaka J., Murase T. et al. Remarkable responses of metastatic renal cell cancer in multiple organs treated with alphainterferon. J Urol 1986;136(5):1061–2.Takita T., Tanaka J., Murase T. et al. Remarkable responses of metastatic renal cell cancer in multiple organs treated with alphainterferon. J Urol 1986;136(5):1061–2.12. Dudek A.Z., Raza A., Chi M. et al. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer 2013;11(2):155–60.Dudek A.Z., Raza A., Chi M. et al. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer 2013;11(2):155–60.13. Massard C., Zonierek J., Gross-Goupil M. et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010;21(5):1027–31.Massard C., Zonierek J., Gross-Goupil M. et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010;21(5):1027–31.14. Gore M.E., Hariharan S., Porta C. et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011;(117):501–9.Gore M.E., Hariharan S., Porta C. et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011;(117):501–9.15. Koutras A.K., Krikelis L., Alexandrou N. et al. Brain Metastasis in Renal Cell Cancer Responding to Sunitinib. Anticancer Research 2007;(27):4255–8.Koutras A.K., Krikelis L., Alexandrou N. et al. Brain Metastasis in Renal Cell Cancer Responding to Sunitinib. Anticancer Research 2007;(27):4255–8.16. Shah A.Y., Karam J.A., Lim Z.D. et al. Clinical and pathological complete remission in a atient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy? Urol Case Rep 2015;3(2):18–20.Shah A.Y., Karam J.A., Lim Z.D. et al. Clinical and pathological complete remission in a atient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy? Urol Case Rep 2015;3(2):18–20.17. Valcamonico F., Ferrari V., Amoroso V. et al. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol 2009;(91):47–50.Valcamonico F., Ferrari V., Amoroso V. et al. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol 2009;(91):47–50.18. Walid M.S., Johnston K.W. Successful treatment of a brain-metastatized renal cell carcinoma. Ger Med Sci 2009;(1–2):7.Walid M.S., Johnston K.W. Successful treatment of a brain-metastatized renal cell carcinoma. Ger Med Sci 2009;(1–2):7.19. Hiles J.J., Kolesar J.M. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 2008;65(2):123–31.Hiles J.J., Kolesar J.M. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 2008;65(2):123–31.